FDA IID release April 2016: Inactive Ingredient Database File

Browse every parsed inactive-ingredient row and every release-scoped FDA change-log record from this recovered source artifact.

FDA source artifact

Download archived FDA source ZIP

Edition: April 2016: Inactive Ingredient Database File
Edition date: 2016-04-01
Snapshot ID: 2ecdbb4431ce8b2f0eca9799d2ffcb1d187eea33b95fafd31be26d79a17049f3
Source member: iig-apr2016.csv
Source bytes: 600,432
Source SHA-256: 9ca134e2271ee2b2f27e011cf3fb2c2dcae8571b17a8c19d4d4575861c5057ef
Archived object key: import-staging/iid/raw/9ca134e2271ee2b2f27e011cf3fb2c2dcae8571b17a8c19d4d4575861c5057ef/iid-edition-041.zip
Parser version: iid-2026-08-01-v1
Imported: 2026-08-01 22:11:32

IID snapshot rows#

These are the actual parsed IID rows from this one FDA source artifact. Raw FDA values are preserved and HTML-escaped.


[".ALPHA.-TERPINEOL", "TOPICAL", "LOTION", "98555", "21334LVV8W", "11", "%W/V", ""]
[".ALPHA.-TERPINEOL", "TOPICAL", "SOLUTION", "98555", "21334LVV8W", "", "NA", ""]
[".ALPHA.-TOCOPHEROL", "BUCCAL", "FILM, SOLUBLE", "", "H4N855PNZ1", "0.07", "MG", "Y"]
[".ALPHA.-TOCOPHEROL", "ORAL", "CAPSULE", "", "H4N855PNZ1", "1", "MG", "Y"]
[".ALPHA.-TOCOPHEROL", "ORAL", "CAPSULE, SOFT GELATIN", "", "H4N855PNZ1", "1", "MG", "Y"]
[".ALPHA.-TOCOPHEROL", "ORAL", "SOLUTION", "", "H4N855PNZ1", "1.05", "MG/1ML", "Y"]
[".ALPHA.-TOCOPHEROL", "ORAL", "TABLET", "", "H4N855PNZ1", "0.7", "MG", "Y"]
[".ALPHA.-TOCOPHEROL", "ORAL", "TABLET (IMMED./COMP. RELEASE), UNCOATED, CHEWABLE", "", "H4N855PNZ1", "0.1", "MG", "Y"]
[".ALPHA.-TOCOPHEROL", "ORAL", "TABLET, FILM COATED", "", "H4N855PNZ1", "42.5", "MG", "Y"]
[".ALPHA.-TOCOPHEROL", "ORAL", "TABLET, SUSTAINED ACTION", "", "H4N855PNZ1", "1.34", "MG", "Y"]
[".ALPHA.-TOCOPHEROL", "ORAL-21", "TABLET", "", "H4N855PNZ1", "0.1", "MG", "Y"]
[".ALPHA.-TOCOPHEROL", "ORAL-28", "TABLET", "", "H4N855PNZ1", "0.1", "MG", "Y"]
[".ALPHA.-TOCOPHEROL", "TOPICAL", "OINTMENT", "", "H4N855PNZ1", "0.001", "%W/W", "Y"]
[".ALPHA.-TOCOPHEROL", "TOPICAL", "PATCH", "", "H4N855PNZ1", "0.099", "MG", "Y"]
[".ALPHA.-TOCOPHEROL", "TRANSDERMAL", "PATCH", "", "H4N855PNZ1", "", "NA", "Y"]
[".ALPHA.-TOCOPHEROL", "INTRAVENOUS", "INJECTION, POWDER, LYOPHILIZED, FOR LIPOSOMAL SUSPENSION", "1406184", "H4N855PNZ1", "0.064", "%", ""]
[".ALPHA.-TOCOPHEROL", "ORAL", "CAPSULE", "1406184", "H4N855PNZ1", "0.5", "MG", "Y"]
[".ALPHA.-TOCOPHEROL", "ORAL", "CAPSULE, SOFT GELATIN", "1406184", "H4N855PNZ1", "5", "MG", ""]
[".ALPHA.-TOCOPHEROL", "ORAL", "TABLET", "1406184", "H4N855PNZ1", "0.3", "MG", "Y"]
[".ALPHA.-TOCOPHEROL", "ORAL", "TABLET, EXTENDED RELEASE", "1406184", "H4N855PNZ1", "0.2", "MG", ""]
[".ALPHA.-TOCOPHEROL", "TOPICAL", "OINTMENT", "1406184", "H4N855PNZ1", "0.002", "%W/W", ""]
[".ALPHA.-TOCOPHEROL", "TOPICAL", "SUSPENSION", "1406184", "H4N855PNZ1", "", "NA", "Y"]
[".ALPHA.-TOCOPHEROL ACETATE", "BUCCAL", "FILM", "", "9E8X80D2L0", "0.088", "MG", "Y"]
[".ALPHA.-TOCOPHEROL ACETATE", "ORAL", "CAPSULE", "", "9E8X80D2L0", "2", "MG", "Y"]
[".ALPHA.-TOCOPHEROL ACETATE", "ORAL", "TABLET", "", "9E8X80D2L0", "0.5", "MG", ""]
[".ALPHA.-TOCOPHEROL ACETATE, DL-", "TOPICAL", "EMULSION, AEROSOL FOAM", "52225204", "WR1WPI7EW8", "0.002", "%W/W", ""]
[".ALPHA.-TOCOPHEROL ACETATE, DL-", "TOPICAL", "OINTMENT", "52225204", "WR1WPI7EW8", "0.002", "%W/W", ""]
[".ALPHA.-TOCOPHEROL, DL-", "INTRAVENOUS", "SOLUTION, CONCENTRATE", "10191410", "7QWA1RIO01", "0.075", "%", ""]
[".ALPHA.-TOCOPHEROL, DL-", "ORAL", "CAPSULE, SOFT GELATIN", "10191410", "7QWA1RIO01", "0.08", "MG", ""]
[".ALPHA.-TOCOPHEROL, DL-", "ORAL", "TABLET", "10191410", "7QWA1RIO01", "0.08", "MG", ""]
[".ALPHA.-TOCOPHEROL, DL-", "ORAL-28", "TABLET", "10191410", "7QWA1RIO01", "0.9", "MG", ""]
[".ALPHA.-TOCOPHEROL, DL-", "TOPICAL", "AEROSOL, FOAM", "10191410", "7QWA1RIO01", "0.002", "%W/W", ""]
[".ALPHA.-TOCOPHEROL, DL-", "TOPICAL", "OINTMENT", "10191410", "7QWA1RIO01", "0.002", "%W/W", ""]
[".BETA.-CAROTENE", "ORAL", "EMULSION", "7235407", "01YAE03M7J", "", "NA", ""]
[".BETA.-CYCLODEXTRIN SULFOBUTYL ETHER SODIUM", "INTRAVENOUS", "INJECTION", "", "2PP9364507", "67.5", "%", "Y"]
[".BETA.-CYCLODEXTRIN SULFOBUTYL ETHER SODIUM", "INTRAMUSCULAR", "POWDER, FOR INJECTION SOLUTION, LYOPHILIZED, WITH ADDITIVES", "182410000", "2PP9364507", "44.15", "%W/V", "Y"]
[".BETA.-CYCLODEXTRIN SULFOBUTYL ETHER SODIUM", "INTRAVENOUS", "POWDER, FOR INJECTION SOLUTION", "182410000", "2PP9364507", "16", "%", "Y"]
[".BETA.-CYCLODEXTRIN SULFOBUTYL ETHER SODIUM", "INTRAVENOUS", "POWDER, FOR INJECTION SOLUTION, LYOPHILIZED", "182410000", "2PP9364507", "10", "%", "Y"]
[".BETA.-CYCLODEXTRIN SULFOBUTYL ETHER SODIUM", "IV - SC", "SOLUTION, INJECTION", "182410000", "2PP9364507", "", "NA", "Y"]
[".BETA.-CYCLODEXTRIN SULFOBUTYL ETHER SODIUM", "IV(INFUSION)", "POWDER, FOR INJECTION SOLUTION, LYOPHILIZED", "182410000", "2PP9364507", "16", "%", "Y"]
[".BETA.-IONONE", "NASAL", "SPRAY, METERED", "79776", "A7NRR1HLH6", "1", "%", ""]
["1-(PHENYLAZO)-2-NAPHTHYLAMINE", "ORAL", "CAPSULE", "85847", "3VSI4D701X", "0.13", "MG", ""]
["1-(PHENYLAZO)-2-NAPHTHYLAMINE", "ORAL", "TABLET", "85847", "3VSI4D701X", "0.2", "MG", ""]
["1,2,6-HEXANETRIOL", "TOPICAL", "EMULSION, CREAM", "106694", "W45XXM0XWE", "5", "%W/W", ""]
["1,2-DIMYRISTOYL-SN-GLYCERO-3-(PHOSPHO-S-(1-GLYCEROL))", "IV(INFUSION)", "SUSPENSION, INJECTION", "57618287", "L34S99KZCX", "0.15", "%", ""]
["1,2-DIMYRISTOYL-SN-GLYCERO-3-PHOSPHOCHOLINE", "INTRAVENOUS", "POWDER, FOR INJECTION SOLUTION, LYOPHILIZED", "18194246", "52QK2NZ2T0", "7.05", "%", ""]
["1,2-DIMYRISTOYL-SN-GLYCERO-3-PHOSPHOCHOLINE", "IV(INFUSION)", "SUSPENSION, INJECTION", "18194246", "52QK2NZ2T0", "0.34", "%", ""]
["1,2-DIOLEOYL-SN-GLYCERO-3-PHOSPHOCHOLINE", "EPIDURAL", "INJECTION, SUSPENSION, LIPOSOMAL", "4235954", "H026DM5V6U", "0.42", "%", ""]
["1,2-DIPALMITOYL-SN-GLYCERO-3-(PHOSPHO-RAC-(1-GLYCEROL))", "EPIDURAL", "INJECTION, SUSPENSION, LIPOSOMAL", "74313954", "5045XZ24IY", "0.045", "%", ""]
["1,2-DISTEAROYL-SN-GLYCERO-3-(PHOSPHO-RAC-(1-GLYCEROL))", "INTRAVENOUS", "INJECTION, POWDER, LYOPHILIZED, FOR LIPOSOMAL SUSPENSION", "217939974", "Z16Y0357CV", "8.4", "%", ""]

Source row, Ingredient, UNII table
Source row	Ingredient	UNII	CAS	Dosage form	Route	Potency	Record updated	Row SHA-256	Raw source values
2	.ALPHA.-TERPINEOL	21334LVV8W	98555	LOTION	TOPICAL	11 %W/V		`154b41628e0c…`	Raw FDA values `[".ALPHA.-TERPINEOL", "TOPICAL", "LOTION", "98555", "21334LVV8W", "11", "%W/V", ""]`
3	.ALPHA.-TERPINEOL	21334LVV8W	98555	SOLUTION	TOPICAL	NA		`c66afc1bed2c…`	Raw FDA values `[".ALPHA.-TERPINEOL", "TOPICAL", "SOLUTION", "98555", "21334LVV8W", "", "NA", ""]`
4	.ALPHA.-TOCOPHEROL	H4N855PNZ1		FILM, SOLUBLE	BUCCAL	0.07 MG	Y	`e2c00af411e3…`	Raw FDA values `[".ALPHA.-TOCOPHEROL", "BUCCAL", "FILM, SOLUBLE", "", "H4N855PNZ1", "0.07", "MG", "Y"]`
5	.ALPHA.-TOCOPHEROL	H4N855PNZ1		CAPSULE	ORAL	1 MG	Y	`6cfd85741a50…`	Raw FDA values `[".ALPHA.-TOCOPHEROL", "ORAL", "CAPSULE", "", "H4N855PNZ1", "1", "MG", "Y"]`
6	.ALPHA.-TOCOPHEROL	H4N855PNZ1		CAPSULE, SOFT GELATIN	ORAL	1 MG	Y	`46e24143e508…`	Raw FDA values `[".ALPHA.-TOCOPHEROL", "ORAL", "CAPSULE, SOFT GELATIN", "", "H4N855PNZ1", "1", "MG", "Y"]`
7	.ALPHA.-TOCOPHEROL	H4N855PNZ1		SOLUTION	ORAL	1.05 MG/1ML	Y	`c91b2f1afaa2…`	Raw FDA values `[".ALPHA.-TOCOPHEROL", "ORAL", "SOLUTION", "", "H4N855PNZ1", "1.05", "MG/1ML", "Y"]`
8	.ALPHA.-TOCOPHEROL	H4N855PNZ1		TABLET	ORAL	0.7 MG	Y	`ce0b1a4107db…`	Raw FDA values `[".ALPHA.-TOCOPHEROL", "ORAL", "TABLET", "", "H4N855PNZ1", "0.7", "MG", "Y"]`
9	.ALPHA.-TOCOPHEROL	H4N855PNZ1		TABLET (IMMED./COMP. RELEASE), UNCOATED, CHEWABLE	ORAL	0.1 MG	Y	`7b7c2e11ad92…`	Raw FDA values `[".ALPHA.-TOCOPHEROL", "ORAL", "TABLET (IMMED./COMP. RELEASE), UNCOATED, CHEWABLE", "", "H4N855PNZ1", "0.1", "MG", "Y"]`
10	.ALPHA.-TOCOPHEROL	H4N855PNZ1		TABLET, FILM COATED	ORAL	42.5 MG	Y	`44393a6a502a…`	Raw FDA values `[".ALPHA.-TOCOPHEROL", "ORAL", "TABLET, FILM COATED", "", "H4N855PNZ1", "42.5", "MG", "Y"]`
11	.ALPHA.-TOCOPHEROL	H4N855PNZ1		TABLET, SUSTAINED ACTION	ORAL	1.34 MG	Y	`4d2103f802cc…`	Raw FDA values `[".ALPHA.-TOCOPHEROL", "ORAL", "TABLET, SUSTAINED ACTION", "", "H4N855PNZ1", "1.34", "MG", "Y"]`
12	.ALPHA.-TOCOPHEROL	H4N855PNZ1		TABLET	ORAL-21	0.1 MG	Y	`ff459c56ac86…`	Raw FDA values `[".ALPHA.-TOCOPHEROL", "ORAL-21", "TABLET", "", "H4N855PNZ1", "0.1", "MG", "Y"]`
13	.ALPHA.-TOCOPHEROL	H4N855PNZ1		TABLET	ORAL-28	0.1 MG	Y	`6b9b1662df64…`	Raw FDA values `[".ALPHA.-TOCOPHEROL", "ORAL-28", "TABLET", "", "H4N855PNZ1", "0.1", "MG", "Y"]`
14	.ALPHA.-TOCOPHEROL	H4N855PNZ1		OINTMENT	TOPICAL	0.001 %W/W	Y	`4c7211e88e8b…`	Raw FDA values `[".ALPHA.-TOCOPHEROL", "TOPICAL", "OINTMENT", "", "H4N855PNZ1", "0.001", "%W/W", "Y"]`
15	.ALPHA.-TOCOPHEROL	H4N855PNZ1		PATCH	TOPICAL	0.099 MG	Y	`4af4d48d845f…`	Raw FDA values `[".ALPHA.-TOCOPHEROL", "TOPICAL", "PATCH", "", "H4N855PNZ1", "0.099", "MG", "Y"]`
16	.ALPHA.-TOCOPHEROL	H4N855PNZ1		PATCH	TRANSDERMAL	NA	Y	`afd4d19e5beb…`	Raw FDA values `[".ALPHA.-TOCOPHEROL", "TRANSDERMAL", "PATCH", "", "H4N855PNZ1", "", "NA", "Y"]`
17	.ALPHA.-TOCOPHEROL	H4N855PNZ1	1406184	INJECTION, POWDER, LYOPHILIZED, FOR LIPOSOMAL SUSPENSION	INTRAVENOUS	0.064 %		`b407760fe2dc…`	Raw FDA values `[".ALPHA.-TOCOPHEROL", "INTRAVENOUS", "INJECTION, POWDER, LYOPHILIZED, FOR LIPOSOMAL SUSPENSION", "1406184", "H4N855PNZ1", "0.064", "%", ""]`
18	.ALPHA.-TOCOPHEROL	H4N855PNZ1	1406184	CAPSULE	ORAL	0.5 MG	Y	`8230c851b1af…`	Raw FDA values `[".ALPHA.-TOCOPHEROL", "ORAL", "CAPSULE", "1406184", "H4N855PNZ1", "0.5", "MG", "Y"]`
19	.ALPHA.-TOCOPHEROL	H4N855PNZ1	1406184	CAPSULE, SOFT GELATIN	ORAL	5 MG		`ffceeb2c27f6…`	Raw FDA values `[".ALPHA.-TOCOPHEROL", "ORAL", "CAPSULE, SOFT GELATIN", "1406184", "H4N855PNZ1", "5", "MG", ""]`
20	.ALPHA.-TOCOPHEROL	H4N855PNZ1	1406184	TABLET	ORAL	0.3 MG	Y	`a0d7c477e50d…`	Raw FDA values `[".ALPHA.-TOCOPHEROL", "ORAL", "TABLET", "1406184", "H4N855PNZ1", "0.3", "MG", "Y"]`
21	.ALPHA.-TOCOPHEROL	H4N855PNZ1	1406184	TABLET, EXTENDED RELEASE	ORAL	0.2 MG		`cf49d490d3ce…`	Raw FDA values `[".ALPHA.-TOCOPHEROL", "ORAL", "TABLET, EXTENDED RELEASE", "1406184", "H4N855PNZ1", "0.2", "MG", ""]`
22	.ALPHA.-TOCOPHEROL	H4N855PNZ1	1406184	OINTMENT	TOPICAL	0.002 %W/W		`a32f625772c9…`	Raw FDA values `[".ALPHA.-TOCOPHEROL", "TOPICAL", "OINTMENT", "1406184", "H4N855PNZ1", "0.002", "%W/W", ""]`
23	.ALPHA.-TOCOPHEROL	H4N855PNZ1	1406184	SUSPENSION	TOPICAL	NA	Y	`7574804b0e74…`	Raw FDA values `[".ALPHA.-TOCOPHEROL", "TOPICAL", "SUSPENSION", "1406184", "H4N855PNZ1", "", "NA", "Y"]`
24	.ALPHA.-TOCOPHEROL ACETATE	9E8X80D2L0		FILM	BUCCAL	0.088 MG	Y	`5ce83f22dbaa…`	Raw FDA values `[".ALPHA.-TOCOPHEROL ACETATE", "BUCCAL", "FILM", "", "9E8X80D2L0", "0.088", "MG", "Y"]`
25	.ALPHA.-TOCOPHEROL ACETATE	9E8X80D2L0		CAPSULE	ORAL	2 MG	Y	`402d6b503027…`	Raw FDA values `[".ALPHA.-TOCOPHEROL ACETATE", "ORAL", "CAPSULE", "", "9E8X80D2L0", "2", "MG", "Y"]`
26	.ALPHA.-TOCOPHEROL ACETATE	9E8X80D2L0		TABLET	ORAL	0.5 MG		`cdacff4ef89a…`	Raw FDA values `[".ALPHA.-TOCOPHEROL ACETATE", "ORAL", "TABLET", "", "9E8X80D2L0", "0.5", "MG", ""]`
27	.ALPHA.-TOCOPHEROL ACETATE, DL-	WR1WPI7EW8	52225204	EMULSION, AEROSOL FOAM	TOPICAL	0.002 %W/W		`c073eeccb00b…`	Raw FDA values `[".ALPHA.-TOCOPHEROL ACETATE, DL-", "TOPICAL", "EMULSION, AEROSOL FOAM", "52225204", "WR1WPI7EW8", "0.002", "%W/W", ""]`
28	.ALPHA.-TOCOPHEROL ACETATE, DL-	WR1WPI7EW8	52225204	OINTMENT	TOPICAL	0.002 %W/W		`19b31f8dc2cb…`	Raw FDA values `[".ALPHA.-TOCOPHEROL ACETATE, DL-", "TOPICAL", "OINTMENT", "52225204", "WR1WPI7EW8", "0.002", "%W/W", ""]`
29	.ALPHA.-TOCOPHEROL, DL-	7QWA1RIO01	10191410	SOLUTION, CONCENTRATE	INTRAVENOUS	0.075 %		`898684f07ce7…`	Raw FDA values `[".ALPHA.-TOCOPHEROL, DL-", "INTRAVENOUS", "SOLUTION, CONCENTRATE", "10191410", "7QWA1RIO01", "0.075", "%", ""]`
30	.ALPHA.-TOCOPHEROL, DL-	7QWA1RIO01	10191410	CAPSULE, SOFT GELATIN	ORAL	0.08 MG		`6662662003ec…`	Raw FDA values `[".ALPHA.-TOCOPHEROL, DL-", "ORAL", "CAPSULE, SOFT GELATIN", "10191410", "7QWA1RIO01", "0.08", "MG", ""]`
31	.ALPHA.-TOCOPHEROL, DL-	7QWA1RIO01	10191410	TABLET	ORAL	0.08 MG		`7162d4e944c1…`	Raw FDA values `[".ALPHA.-TOCOPHEROL, DL-", "ORAL", "TABLET", "10191410", "7QWA1RIO01", "0.08", "MG", ""]`
32	.ALPHA.-TOCOPHEROL, DL-	7QWA1RIO01	10191410	TABLET	ORAL-28	0.9 MG		`2c675718a3c4…`	Raw FDA values `[".ALPHA.-TOCOPHEROL, DL-", "ORAL-28", "TABLET", "10191410", "7QWA1RIO01", "0.9", "MG", ""]`
33	.ALPHA.-TOCOPHEROL, DL-	7QWA1RIO01	10191410	AEROSOL, FOAM	TOPICAL	0.002 %W/W		`62676f600049…`	Raw FDA values `[".ALPHA.-TOCOPHEROL, DL-", "TOPICAL", "AEROSOL, FOAM", "10191410", "7QWA1RIO01", "0.002", "%W/W", ""]`
34	.ALPHA.-TOCOPHEROL, DL-	7QWA1RIO01	10191410	OINTMENT	TOPICAL	0.002 %W/W		`d7f0f55dd77c…`	Raw FDA values `[".ALPHA.-TOCOPHEROL, DL-", "TOPICAL", "OINTMENT", "10191410", "7QWA1RIO01", "0.002", "%W/W", ""]`
35	.BETA.-CAROTENE	01YAE03M7J	7235407	EMULSION	ORAL	NA		`0709965a073a…`	Raw FDA values `[".BETA.-CAROTENE", "ORAL", "EMULSION", "7235407", "01YAE03M7J", "", "NA", ""]`
36	.BETA.-CYCLODEXTRIN SULFOBUTYL ETHER SODIUM	2PP9364507		INJECTION	INTRAVENOUS	67.5 %	Y	`3ac05cb94bf6…`	Raw FDA values `[".BETA.-CYCLODEXTRIN SULFOBUTYL ETHER SODIUM", "INTRAVENOUS", "INJECTION", "", "2PP9364507", "67.5", "%", "Y"]`
37	.BETA.-CYCLODEXTRIN SULFOBUTYL ETHER SODIUM	2PP9364507	182410000	POWDER, FOR INJECTION SOLUTION, LYOPHILIZED, WITH ADDITIVES	INTRAMUSCULAR	44.15 %W/V	Y	`d3ff229d60b8…`	Raw FDA values `[".BETA.-CYCLODEXTRIN SULFOBUTYL ETHER SODIUM", "INTRAMUSCULAR", "POWDER, FOR INJECTION SOLUTION, LYOPHILIZED, WITH ADDITIVES", "182410000", "2PP9364507", "44.15", "%W/V", "Y"]`
38	.BETA.-CYCLODEXTRIN SULFOBUTYL ETHER SODIUM	2PP9364507	182410000	POWDER, FOR INJECTION SOLUTION	INTRAVENOUS	16 %	Y	`edd3e28b6a51…`	Raw FDA values `[".BETA.-CYCLODEXTRIN SULFOBUTYL ETHER SODIUM", "INTRAVENOUS", "POWDER, FOR INJECTION SOLUTION", "182410000", "2PP9364507", "16", "%", "Y"]`
39	.BETA.-CYCLODEXTRIN SULFOBUTYL ETHER SODIUM	2PP9364507	182410000	POWDER, FOR INJECTION SOLUTION, LYOPHILIZED	INTRAVENOUS	10 %	Y	`2bbd78cb49c7…`	Raw FDA values `[".BETA.-CYCLODEXTRIN SULFOBUTYL ETHER SODIUM", "INTRAVENOUS", "POWDER, FOR INJECTION SOLUTION, LYOPHILIZED", "182410000", "2PP9364507", "10", "%", "Y"]`
40	.BETA.-CYCLODEXTRIN SULFOBUTYL ETHER SODIUM	2PP9364507	182410000	SOLUTION, INJECTION	IV - SC	NA	Y	`dcaf2fb17895…`	Raw FDA values `[".BETA.-CYCLODEXTRIN SULFOBUTYL ETHER SODIUM", "IV - SC", "SOLUTION, INJECTION", "182410000", "2PP9364507", "", "NA", "Y"]`
41	.BETA.-CYCLODEXTRIN SULFOBUTYL ETHER SODIUM	2PP9364507	182410000	POWDER, FOR INJECTION SOLUTION, LYOPHILIZED	IV(INFUSION)	16 %	Y	`1f226c0f6de0…`	Raw FDA values `[".BETA.-CYCLODEXTRIN SULFOBUTYL ETHER SODIUM", "IV(INFUSION)", "POWDER, FOR INJECTION SOLUTION, LYOPHILIZED", "182410000", "2PP9364507", "16", "%", "Y"]`
42	.BETA.-IONONE	A7NRR1HLH6	79776	SPRAY, METERED	NASAL	1 %		`3f79b7b5066e…`	Raw FDA values `[".BETA.-IONONE", "NASAL", "SPRAY, METERED", "79776", "A7NRR1HLH6", "1", "%", ""]`
43	1-(PHENYLAZO)-2-NAPHTHYLAMINE	3VSI4D701X	85847	CAPSULE	ORAL	0.13 MG		`21daff092360…`	Raw FDA values `["1-(PHENYLAZO)-2-NAPHTHYLAMINE", "ORAL", "CAPSULE", "85847", "3VSI4D701X", "0.13", "MG", ""]`
44	1-(PHENYLAZO)-2-NAPHTHYLAMINE	3VSI4D701X	85847	TABLET	ORAL	0.2 MG		`ec782259e95f…`	Raw FDA values `["1-(PHENYLAZO)-2-NAPHTHYLAMINE", "ORAL", "TABLET", "85847", "3VSI4D701X", "0.2", "MG", ""]`
45	1,2,6-HEXANETRIOL	W45XXM0XWE	106694	EMULSION, CREAM	TOPICAL	5 %W/W		`cdeb9efeff8b…`	Raw FDA values `["1,2,6-HEXANETRIOL", "TOPICAL", "EMULSION, CREAM", "106694", "W45XXM0XWE", "5", "%W/W", ""]`
46	1,2-DIMYRISTOYL-SN-GLYCERO-3-(PHOSPHO-S-(1-GLYCEROL))	L34S99KZCX	57618287	SUSPENSION, INJECTION	IV(INFUSION)	0.15 %		`b4f588155de6…`	Raw FDA values `["1,2-DIMYRISTOYL-SN-GLYCERO-3-(PHOSPHO-S-(1-GLYCEROL))", "IV(INFUSION)", "SUSPENSION, INJECTION", "57618287", "L34S99KZCX", "0.15", "%", ""]`
47	1,2-DIMYRISTOYL-SN-GLYCERO-3-PHOSPHOCHOLINE	52QK2NZ2T0	18194246	POWDER, FOR INJECTION SOLUTION, LYOPHILIZED	INTRAVENOUS	7.05 %		`8ca2937b385b…`	Raw FDA values `["1,2-DIMYRISTOYL-SN-GLYCERO-3-PHOSPHOCHOLINE", "INTRAVENOUS", "POWDER, FOR INJECTION SOLUTION, LYOPHILIZED", "18194246", "52QK2NZ2T0", "7.05", "%", ""]`
48	1,2-DIMYRISTOYL-SN-GLYCERO-3-PHOSPHOCHOLINE	52QK2NZ2T0	18194246	SUSPENSION, INJECTION	IV(INFUSION)	0.34 %		`33c351c17821…`	Raw FDA values `["1,2-DIMYRISTOYL-SN-GLYCERO-3-PHOSPHOCHOLINE", "IV(INFUSION)", "SUSPENSION, INJECTION", "18194246", "52QK2NZ2T0", "0.34", "%", ""]`
49	1,2-DIOLEOYL-SN-GLYCERO-3-PHOSPHOCHOLINE	H026DM5V6U	4235954	INJECTION, SUSPENSION, LIPOSOMAL	EPIDURAL	0.42 %		`6b1569142ee8…`	Raw FDA values `["1,2-DIOLEOYL-SN-GLYCERO-3-PHOSPHOCHOLINE", "EPIDURAL", "INJECTION, SUSPENSION, LIPOSOMAL", "4235954", "H026DM5V6U", "0.42", "%", ""]`
50	1,2-DIPALMITOYL-SN-GLYCERO-3-(PHOSPHO-RAC-(1-GLYCEROL))	5045XZ24IY	74313954	INJECTION, SUSPENSION, LIPOSOMAL	EPIDURAL	0.045 %		`3c8c1947f89e…`	Raw FDA values `["1,2-DIPALMITOYL-SN-GLYCERO-3-(PHOSPHO-RAC-(1-GLYCEROL))", "EPIDURAL", "INJECTION, SUSPENSION, LIPOSOMAL", "74313954", "5045XZ24IY", "0.045", "%", ""]`
51	1,2-DISTEAROYL-SN-GLYCERO-3-(PHOSPHO-RAC-(1-GLYCEROL))	Z16Y0357CV	217939974	INJECTION, POWDER, LYOPHILIZED, FOR LIPOSOMAL SUSPENSION	INTRAVENOUS	8.4 %		`c04b11155e13…`	Raw FDA values `["1,2-DISTEAROYL-SN-GLYCERO-3-(PHOSPHO-RAC-(1-GLYCEROL))", "INTRAVENOUS", "INJECTION, POWDER, LYOPHILIZED, FOR LIPOSOMAL SUSPENSION", "217939974", "Z16Y0357CV", "8.4", "%", ""]`

IID release change log#

Release-scoped records: FDA change-log rows are published exactly as recovered for this release. The source does not provide a safe ingredient-row key, so these records are not attributed to any ingredient above.

This recovered release contains no FDA change-log rows.